Next Investors logo grey

MGC Pharmaceuticals on high as Malta legalises medical cannabis

Published 21-MAY-2018 11:39 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Specialist pot-stock, MGC Pharmaceuticals (ASX:MXC), this morning revealed that the Maltese parliament has passed final legislation for the approval of medicinal cannabis production.

This latest development is a major milestone for MXC in obtaining its formal contract for a fully licensed medicinal cannabis manufacturing facility in Malta.

MXC already has Malta Enterprise approval and a contract for its pot production facility. The company says it is now expecting to have final formal agreements signed in the coming weeks from the Malta Medicine Authority.

Malta Enterprise, the government agency responsible for attracting foreign investment, together with Malta Industrial Parks, has identified 4,000 square kilometres of land for MXC’s facility.

Planning has now kicked off for construction, and MXC anticipates approval to immediately begin construction will follow receipt of its licence and final contracts.

The production facility will house a research hub and a GMP-certified production and manufacturing facility. This will provide scope for MXC’s vision of an EU-based, fully vertically integrated, ‘seed to pharma’ medical cannabis operation.

Under this agreement, MXC will be able to produce all THC (tetrahydrocannabinol) and CBD (cannabidiol) strains of pharmaceutical-grade cannabis into key European markets. MXC will obtain GMP certification for the facility, and will comply with all Maltese medicinal cannabis licenses and permits.

With its pot-perfect climate and vantage position within the EU, Malta makes for an ideal location for MXC’s production and cultivation facility. It also presents an appealing business and cost environment compared to other EU locations, enabling cost-effective investment and direct leverage into the EU.

The EU medical cannabis market is expected to be worth $56 billion by 2020, with especially rapid growth in areas like Germany, where the market is currently worth $17.5 billion and observes a lower wholesale price of raw materials (3.5€ per gram).

How much of this market MXC is able to attract remains to be seen so investors should seek professional financial advice for further information if considering this stock for their portfolio.

Roby Zomer, MXC co-founder and managing director, said: “I am pleased to inform you that the production of cannabis for medical use has now become legal and regulated under Maltese legislation, and a plot of land within one of the Maltese industrial zones has been designated to us for our project. Once the licence by the Malta Medicines Authority is issued, we will be able to commence work on the project in Malta.”

Following this morning’s announcement, MXC is in an ascendant position, currently at 7.2 cents.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.